Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
22 results
D3.66 - National Survey on Perioperative Hypersensitivity Reactions: Clinical and Epidemiological Insights from Spanish Hospitals
D3.67 - Desensitization to Pertuzumab in a Patient with a Mixed Hipersensitivity Reaction
D3.69 - Tissue-Specific Allergen Distribution in Blue Swimmer Crab (Portunus pelagicus): Implications for Shellfish Allergy Diagnostics
D3.70 - Multiple Food Protein-Induced Enteropathy Syndrome: The Role of Skin Patch Testing in Guiding Effective Decision-Making
D3.71 - Anaphylaxis Induced by Macrogol: A Case Report
D3.72 - Utility of Basophil Activation Testing in Drug and Peanut Allergy: Concordance with Clinical Outcomes
D3.73 - Review of skin testing for delay hypersensitivity drug reactions, possible covariates involved in the results
D3.77 - Hypersensitivity Reactions to Iodinated Contrast Media: A Single-Center Experience
D3.78 - A rare case of scombroid syndrome with hypotension and biphasic course
D3.79 - Occupational Asthma due to Inhaled Mare's Milk Exposure and Anaphylaxis Associated with Plantago ovata
D3.82 - Could Lipid Transfer Protein Induced Anaphylaxis Be a Surprising Outcome of Sleeve Gastrectomy?
D3.419 - Prevalence of physical urticaria hives in patients with systemic mastocytosis and their relation to disease course – preliminary data
D3.411 - Targeting MRGPRX2 for the Treatment of Mast Cell-Driven Diseases
D3.412 - MRGPRX2 Specific Activation Signature is Enriched in Atopic Dermatitis Lesions and Wheals from Chronic Spontaneous Urticaria Compared to Adjacent Healthy Skin
D3.413 - Development of the Mastocytosis Symptom Severity Daily Diary (MS2D2) for Non-Advanced Systemic Mastocytosis (NonAdvSM) Patients and Establishing Content Validity
D3.414 - The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis
D3.415 - Clinical manifestations of Hereditary alpha-tryptasemia (HaT) in Patients with Mast Cell Activation Syndromes
D3.416 - Hereditary Alpha-Tryptasemia: A Case Series
D3.417 - "Comprehensive Allergological Evaluation and Management of Severe Anaphylaxis to Vespid Venoms: A Case Study"
D3.418 - Modulation of Mast Cell Activation by Histamine H3 and H4 Receptor Antagonists
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download